Thanks for sharing SanFran, and thanks to rndtbl on IV for initially posting. Just like with prostate cancer, there seems to be a lot of promise for BET inhibitors in breast cancer possibly as single agent or a combo agent. Zenith has previously announced that breast cancer would be their next clinical target. Hopefully we get an update soon on the plans/timeline for the Zenith breast cancer clinical program. Of course, these things cost $ so we'll need to hear about that too. But some other companies have already started their breast cancer trials, so hopefully Zenith can enter the race sooner rather than later. This abstract mentioned both ZEN-3694 and ZEN-3309. I don't think I recall ever hearing anything about 3309. Anyone else have any info on 3309?

BDAZ